Product image
Product image
InVivoMAb anti-human PD-L1 (B7-H1)
BE0285
ApplicationsFunctional Assay, Flow Cytometry, ImmunoHistoChemistry, ImmunoHistoChemistry Frozen, Neutralisation/Blocking
Product group Antibodies
ReactivityHuman
Overview
- SupplierBio X Cell
- Product NameInVivoMAb anti-human PD-L1 (B7-H1)
- Delivery Days Customer7
- ApplicationsFunctional Assay, Flow Cytometry, ImmunoHistoChemistry, ImmunoHistoChemistry Frozen, Neutralisation/Blocking
- CertificationResearch Use Only
- ClonalityMonoclonal
- Clone ID29E.2A3
- Concentration4-11 mg/ml
- HostMouse
- IsotypeIgG2b
- Scientific DescriptionThe 29E.2A3 monoclonal antibody reacts with human PD-L1 (programmed death ligand 1) also known as B7-H1 or CD274. PD-L1 is a 40 kDa type I transmembrane protein that belongs to the B7 family of the Ig superfamily. PD-L1 is expressed on T lymphocytes, B lymphocytes, NK cells, dendritic cells, as well as IFNγ stimulated monocytes, epithelial cells and endothelial cells. PD-L1 binds to its receptor, PD-1, found on CD4 and CD8 thymocytes as well as activated T and B lymphocytes and myeloid cells. Engagement of PD-L1 with PD-1 leads to inhibition of TCR-mediated T cell proliferation and cytokine production. PD-L1 is thought to play an important role in tumor immune evasion. Induced PD-L1 expression is common in many tumors and results in increased resistance of tumor cells to CD8 T cell mediated lysis. The 29E.2A3 antibody has been shown to block the binding of PD-1-Ig to PD-L1.
- ReactivityHuman
- Storage Instruction2°C to 8°C
- UNSPSC12352203
References
- Organotypic tumor slice cultures provide a versatile platform for immuno-oncology and drug discovery. Sivakumar R et al., 2019, OncoimmunologyRead more
- Single Domain Antibody-Mediated Blockade of Programmed Death-Ligand 1 on Dendritic Cells Enhances CD8 T-cell Activation and Cytokine Production. Broos K et al., 2019 Aug 7, Vaccines (Basel)Read more
- Differential impact of PD-1 and/or interleukin-10 blockade on HIV-1-specific CD4 T cell and antigen-presenting cell functions. Porichis F et al., 2014 Mar, J VirolRead more
- Human NKT cells direct the differentiation of myeloid APCs that regulate T cell responses via expression of programmed cell death ligands. Hegde S et al., 2011 Aug, J AutoimmunRead more
- Synergistic reversal of intrahepatic HCV-specific CD8 T cell exhaustion by combined PD-1/CTLA-4 blockade. Nakamoto N et al., 2009 Feb, PLoS PathogRead more
- PD-1 ligands, negative regulators for activation of naive, memory, and recently activated human CD4+ T cells. Cai G et al., 2004 Aug, Cell ImmunolRead more
- Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production. Brown JA et al., 2003 Feb 1, J ImmunolRead more
